Market revenue in 2023 | USD 7,377.6 million |
Market revenue in 2030 | USD 10,609.4 million |
Growth rate | 5.3% (CAGR from 2023 to 2030) |
Largest segment | Prostacyclin and prostacyclin analogs |
Fastest growing segment | SGC Stimulators |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Drug Class | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
North America | 2,481.1 | 2,554.1 | 2,782.1 | 2,984.2 | 3,097.3 | 3,220.9 | 3,356.1 | 3,504.3 | 3,667.2 | 3,846.3 | 4,043.9 | 4,262.4 | 4,504.4 | 4.9% |
Europe | 1,546.8 | 1,592.7 | 1,735.2 | 1,861.7 | 1,932.7 | 2,010.2 | 2,095.1 | 2,188.1 | 2,290.2 | 2,402.6 | 2,526.6 | 2,663.7 | 2,815.6 | 4.9% |
Asia Pacific | 669.2 | 701.9 | 778.8 | 850.8 | 899.2 | 952.0 | 1,009.7 | 1,072.9 | 1,142.5 | 1,219.1 | 1,303.8 | 1,397.6 | 1,501.9 | 6.7% |
Latin America | 509.5 | 528.6 | 580.2 | 627.2 | 656.1 | 687.5 | 722.0 | 759.7 | 801.2 | 846.9 | 897.3 | 953.1 | 1,015.1 | 5.7% |
MEA | 366.6 | 382.2 | 421.7 | 458.1 | 481.5 | 507.0 | 534.9 | 565.4 | 599.1 | 636.0 | 676.9 | 722.2 | 772.4 | 6.2% |
Overall | 5,573.2 | 5,759.4 | 6,298.0 | 6,782.0 | 7,066.7 | 7,377.6 | 7,717.7 | 8,090.5 | 8,500.1 | 8,950.9 | 9,448.5 | 9,998.9 | 10,609.4 | 5.3% |
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account